DWJ1351

AssetSmall moleculeAlso FDC Amlodipine/Olmesartan/Rosuvastatin

Fixed-dose combination inhibiting HMG-CoA reductase, L-type calcium channels, and angiotensin II type 1 receptor

Stage
Phase 3
Modality
Small molecule
Target
Lipid and ceramide metabolism
Indications
2
Trials
488
Developers
1

Indications

2
  • Targets and what it contains5
  • Owner and partners1
  • Trials488
  • Evidence for its targets4
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Updated 7 Oct 2026 · 3 sources

Assets